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We analyzed laboratory-based surveillance can-
didemia data from the National Infectious Disease Register
in Finland and reviewed cases of candidemia from one ter-
tiary-care hospital from 1995 to 1999. A total of 479 can-
didemia cases were reported to the Register. The annual
incidence rose from 1.7 per 100,000 population in 1995 to
2.2 in 1999. Species other than Candida albicans account-
ed for 30% of cases without change in the proportion. A
total of 79 cases of candidemia were identified at the hos-
pital; the rate varied from 0.03 to 0.05 per 1,000 patient-
days by year. Predisposing factors included indwelling
catheters (81%), gastrointestinal surgery (27%), hemato-
logic malignancy (25%), other types of surgery (21%), and
solid malignancies (20%). Crude 7-day and 30-day case-
fatality ratios were 15% and 35%, respectively. The rate of
candidemia increased in Finland but is still substantially
lower than in the United States. No shift to non–C. albicans
species could be detected. 
A
number of reports indicate a substantial increase in
candida infections in the United States during the last
2 decades, including a consequent rise in related deaths
and prolonged hospitalization (1–5). Candida sp. have
been shown to be the fourth most common group of organ-
isms causing nosocomial bloodstream infections (BSI) in
the United States (6–9). Reports also suggest an increase in
candidemia in Europe and Australia (10–12). Factors con-
tributing to this trend are a growing population of immuno-
compromised patients and the use of new, aggressive, and
invasive therapeutic strategies (6,13). Although most can-
didemia cases are due to Candida albicans, infections
caused by non–C. albicans species have become more
common (8–9,12,14–18). 
For the most part, the epidemiology of candidemia has
been studied in selected hospitals, which may not be rep-
resentative of all hospitals serving a population
(11–12,19–24). Few population-based studies identifying
trends in the incidence of candidemia over time have been
published, and the absolute numbers for age- and sex-spe-
cific incidence rates have rarely been reported (18,25–28). 
We evaluated trends in the incidence of BSIs caused by
Candida spp. in Finland from 1995 to 1999, using data on
BSIs from laboratory-based surveillance introduced in
1995. We also reviewed the characteristics of candidemia
cases that occurred in the largest tertiary-care hospital in
Finland during the same period. 
Methods
Surveillance and Population 
Finland (population 5.2 million) has five tertiary-care
hospitals, with well-defined catchment populations of 0.71
to 1.66 million. Since 1995, all clinical microbiology lab-
oratories in Finland have reported all bacterial and fungal
isolations from blood, including Candida spp., to the
National Infectious Diseases Register. Detection and
species determination of Candida isolates are performed in
the notifying laboratories according to standard protocols
in use in each laboratory. Data collected with each notifi-
cation include the date of isolation, date of birth, sex, type
of specimen, and place of treatment. 
A case of candidemia was defined as a patient with at
least one blood culture positive for Candida species.
Notifications of the same species of Candida within 3
months after the first diagnostic sample in the same patient
were defined as one case. Isolations of the same species
beyond this time period in the same patient were defined
as separate cases. 
Tertiary-Care Hospital 
Helsinki University Central Hospital (HUCH) is a terti-
ary-care hospital with 1,600 beds that serves a population
of 1.66 million living in the Helsinki area in southern
Finland. In some specialties, such as bone marrow and
solid organ transplantation, HUCH provides national serv-
ice. All patients with at least one blood culture positive for
Candida from January 1995 to December 1999 were retro-
spectively identified from the microbiology laboratory
logbooks of HUCH’s department of bacteriology.
Nosocomial versus community acquisition was defined
according to proposed standard criteria (29). The follow-
ing data were abstracted from patient charts: type of spe-
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bladder catheters in place, cultures taken from these
catheters, and the outcome of the illness. Immuno-
suppressive status was defined as cytotoxic therapy or total
body irradiation <3 months before onset of candidemia or
systemic cortisone (>40 mg per day at onset of cortisone
treatment) <1 month before onset of candidemia. The
annual numbers of patient days and discharges were
acquired from the hospital administration. No guidelines
for systematic antifungal prophylaxis for any patient
groups were in use in HUCH during the study period.
Incidence Rates and Statistical Analysis 
Data from the Finland National Population Registry
from 1995 to 1999 were used as denominators to calculate
age- and sex-specific incidence rates. Average annual inci-
dences during the surveillance period were calculated by
using the total number of cases and population during 1995
to 1999. To evaluate secular trends, rates of candidemia in
different age and sex groups were calculated for each 6-
month period from January 1995 to December 1999. If
changes were detected, Poisson regression model was used
to assess whether the observed changes in the rates were
statistically significant.
Data were analyzed by using Epi Info version 6.04
(available from: URL: http://www.cdc.gov/epiinfo/ei6.htm)
and SPSS for Windows version 11 (Chicago, IL).
Categorical variables were analyzed with the chi-squaretest,
Yates’s correction, or Fisher exact test, as appropriate.
Continuous variables were analyzed by Student t test or the
Mann-Whitney U test, depending on the sample distribution.
Results
A total of 479 candidemia cases were reported to the
National Infectious Diseases Register from 1995 to 1999.
The median age of the patients was 59 years of age (range
0–89 years); 266 (60%) were males. The average annual
incidence of candidemia was 1.9 per 100,000 population
and varied from 1.3 to 2.2 in the five tertiary-care hospital
catchment areas. The incidence increased from 1.7 per
100,000 population in 1995 to 2.2 in 1999. The average
annual incidence of candidemia was highest in infants <1
year of age and lowest in patients 1–15 years of age (Table
1); infants <1 year of age accounted for only 6% of all can-
didemia cases. In all age groups, the incidence was higher
in males than in females. In males 16–65 years of age, the
incidence rose significantly, from 1.0 per 100,000 popula-
tion in 1995 to 2.4 per 100,000 population in 1999 (p<0.05
by Poisson regression); by 1999, the incidence rate for
males was three times the rate in females. No trends were
identified in other age and sex groups. The highest annual
incidence (24.4/100,000 population) occurred in 1999 in
infants <1 year of age, which was primarily caused by C.
albicans (11 cases, 5 of which occurred in one tertiary-care
hospital).
The most frequent Candida sp. encountered was C.
albicans, which caused 335 (70%) cases (Table 2). The
most common non–C. albicans species found was C.
glabrata, followed by C. krusei, C. parapsilosis, and C.
tropicalis. The other species reported were C. pelliculosa
(five cases) and C. rugosa (one case). In 14 (3%) cases, the
species were not specified. The proportion of non–C. albi-
cans species did not increase during the study period.
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Table 1. Annual incidence of candidemia by sex and age group, Finland, 1995–1999 
Rate
a 
Characteristics  1995  1996  1997  1998  1999  1995–1999 
Males (y) 
 <1   12.5  10.0  3.3  6.9  27.3  11.9 (18) 
 1–15  1.2  0.4  0.6  0  0.2  0.5 (12) 
 16–65  1.0  1.9  1.9  2.1  2.4  1.8 (159) 
 >65  7.7  6.3  6.1  9.4  7.7  7.4 (97) 
 All  1.9 (46)  2.1 (53)  2.1 (53)  2.5 (63)  2.8 (71)  2.3 (286) 
Females (y) 
 <1  6.5  3.4  0  3.6  21.3  6.9 (10) 
 1–15  0.6  0.4  0.6  0.2  0.6  0.5 (12) 
 16–65  1.0  0.8  1.1  1.2  0.8  1.0 (84) 
 >65  4.2  4.3  3.4  3.6  4.2  3.9 (87) 
 All  1.5 (39)  1.4 (36)  1.4 (37)  1.5 (39)  1.6 (42)  1.5 (193) 
All (y) 
 <1  9.6  6.6  1.7  5.3  24.4  9.4 (28) 
 1–15  1.0  0.5  0.6  0.1  0.4  0.5 (24) 
 16–65  1.0  1.4  1.5  1.7  1.6  1.4 (243) 
 >65  5.4  5.0  4.4  5.7  5.6  5.2 (184) 
 All  1.7 (85)  1.7 (89)  1.8 (90)  2.0 (102)  2.2 (113)  1.9 (479) 
aCases per 100,000 population (no. of cases). In the study hospital, we identified a total of 86 can-
didemia cases. All but one case were determined to be
nosocomial. Four of the 85 nosocomial candidemia case-
patients were associated with predisposing treatment in
other hospitals, and 2 additional cases-patients, for whom
the clinical information was not available, were excluded,
leaving 79 patients with cases of nosocomial candidemia
for detailed analysis. The median duration of hospital stay
before onset of candidemia was 19 days (range 0–177
days). The median age of the patients was 56 years (range
0–<89 years); 45 (57%) of the patients were male.
The average annual incidence of candidemia at HUCH
was 0.17 per 1,000 discharges (range by year 0.12–0.21)
and 0.04 per 1,000 patient days (range by year 0.03–0.05).
Male patients accounted for 70% of cases <1 year of age
and 66% of those 16–65 years of age, whereas 64% of the
cases >65 years of age were women. We found no increase
in the annual number of cases in men 16–65 years of age,
in contrast to the increasing rate identified in the national
population-based analysis. 
At the onset of candidemia, all cases in the study hos-
pital had at least one predisposing factor. Of 79 cases, 19%
were leukopenic (leukocytes <1 x 10E9/L), and 14% were
neutropenic (neutrophils <0.5 x 10E9/L); 44% were
immunocompromised. Gastrointestinal surgery was the
most common underlying condition, followed by hemato-
logic malignancy, other surgery, and solid malignancies
(Table 3). Solid organ transplantation preceded onset of
candidemia in three cases and bone marrow transplanta-
tion in five. None of the case-patients had HIV infection.
At the onset of candidemia, 18 cases (23%) were treated in
intensive-care units (ICU). Nine (50%) of 18 ICU cases
were treated in neonatal ICUs. These 9 neonatal ICU case-
patients were preterm and constituted 90% of infants <1
year of age; mean gestational age was 28 weeks (range
23–39), and mean birth weight 1,129 g (range 450–3,340
g). Before onset of candidemia, 64 (81%) of case-patients
had a central venous catheter and 33 (42%) had a bladder
catheter in place. Central venous catheter tip culture was
positive for Candida in 28 (44%) of the 64 cases, and urine
culture was positive for Candida in 7 (21%) of the 33
patients with a bladder catheter. Biopsy-proven deep
Candida infection was detected in 9 cases (11%); all had
central venous catheters, and 8 (89%) were operated
before onset of candidemia. 
The most common Candida species at HUCH was C.
albicans (55 cases, 70%), consistent with the overall nation-
al figure (Table 2). For non–C. albicans species, the propor-
tion varied by year from 17% in 1997 to 37% in 1999. In
contrast to the national data, C. parapsilosis was as common
as C. glabrata at the study hospital (six cases each).
Among the 79 patients with candidemia at HUCH, 12
(15%) died within 1 week after onset and 28 (35%) within
1 month. Of those who died, one patient had had preced-
ing treatment in ICU. The patients who died were signifi-
cantly older (median age 51 vs. 60 years of age, p<0.05)
and were more likely to have hematologic malignancies
(60% vs. 27%, p<0.05). 
Discussion
Our nationwide population-based study shows that the
incidence of candidemia in Finland is relatively low.
However, we found a consistent year-to-year increase,
mainly attributable to an increase in the incidence among
men 16–65 years of age. No shift towards non–C. albicans
species was observed. 
We analyzed laboratory-based surveillance data on
BSIs caused by Candida  spp. from nationwide surveil-
lance; therefore, our estimates are representative of the
whole population. The rate we found is one third to one
fourth of the rates reported from the United States
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Table 2. Distribution of Candida spp. causing bloodstream infections, Finland, 1995–1999  
Candida species   1995
a  1996
a  1997
a  1998
a  1999
a  1995–1999
a 
C. albicans  67  (57)  75  (67)  73  (66)  61  (62)  73  (83)  70  (335) 
Non-C. albicans  33  (28)  25  (22)  27  (24)  39  (40)  27  (30)  30  (144) 
 C. glabrata   14  (12)  3  (3)  8  (7)  8  (8)  10  (11)  9  (41) 
 C. krusei   5  (4)  12  (10)  4  (4)  15  (16)  5  (6)  8  (40) 
 C. parapsilosis   11  (9)  1  (1)  6  (5)  6  (6)  5  (6)  5  (27) 
 C. tropicalis   1  (1)  3  (3)  1  (1)  5  (5)  3  (3)  3  (13) 
 Other  2  (2)  6  (5)  8  (7)  5  (5)  4  (4)  5  (23) 
aPercent (no.). 
Table 3. Predisposing factors among 79 patients with nosocomial 
candidemia, Helsinki University Central Hospital, 1995–1999
a 
Predisposing factor  No. (%)
 
Central venous catheter  64  (81) 
Urinary catheter  33  (42) 
Gastrointestinal surgery
b  22  (27) 
Hematologic malignancy   20  (25) 
Other surgery
b  17  (21) 
Solid malignancy  16  (20) 
Diabetes  14  (18) 
Newborn status  9  (11) 
Organ transplantation  8  (10) 
Severe trauma  2  (3) 
aOne patient may have several predisposing factors. 
bSurgery during the same hospital period as candidemia, or within 1 month before 
the first blood culture. (6.0–8.0/100,000 population) (18,25–26). Two of the U.S.
reports included selected urban areas, and the third one
was based on sentinel surveillance implemented in select-
ed laboratories in Iowa (which may not be representative
of the general U.S. population). A nationwide study from
Iceland also documented an increase in the incidence of
candidemia from 1.4 per 100,000 population in 1980 to
1984 to 4.9 in 1995 to 1999 (27). The 1995–1999 rate in
Iceland was more than twice as high as the rate we
observed in Finland during the same period. Another
nationwide study from Norway reporting the annual num-
bers of fungemia cases did not identify any change in the
period 1991–1996 (28). This study also included non-
Candida yeasts. We did not identify any shift towards
non–C. albicans species, in contrast to several reports from
the United States, Australia, and Europe (12,14,16,18) but
in accordance with the nationwide studies from Iceland
and Norway (27,28). 
We observed the highest age-specific incidence rate in
infants <1 year of age. This rate is, however, substantially
lower than the rates reported from the Atlanta and San
Francisco Bay areas in 1992 and 1993 in the same age
group (9.4 vs. 75/100,000 population) (18). We found a
substantial increase in candidemia cases in men 16–65
years of age. The reason for this increase remains
unknown; the detailed analysis in the largest tertiary-care
hospital in Finland during the same period showed no
increase or major change of characteristics in this demo-
graphic subgroup. The Icelandic study showed that the
incidence was highest in the elderly and that the increase
occurred most in the youngest age group (27). The male
dominance we observed is similar to that found in previous
reports (18,25–26,28).
At the largest tertiary-care hospital in Finland, the aver-
age annual incidence of candidemia per 1,000 patient days
was considerably less than that in the United States (0.04
vs. 2.15), as was the rate per 1,000 discharges (0.17 vs.
0.6) (2,30). Incidences similar to the current study have
been reported from European (11,22–24,28) and
Australian tertiary-care centers (12). We observed that
non-nosocomial candidemia was very rare in this tertiary-
care hospital (1/84 cases), which is in strong contrast to
reports from the United States, where one fifth of can-
didemias developed in patients before or on admission to
hospital (18).
Differences in candidemia rates between countries may
also be attributable to differences in the representativeness
of the study population, the prevalence of HIV infection in
the study population, and variations in patterns of health-
care delivery and clinical practices, including the frequen-
cy of using blood cultures in diagnostics. The differences
may also be explained by differences in antibiotic use pat-
terns and resistance situation (28). A previous study from
Finland on nosocomial BSIs showed that Candida spp.
represented only 4% of all findings and the prevalence of
antibiotic resistance among bacterial findings was lower
than in the United States (31). 
The role of fluconazole prophylaxis is well established
in neutropenic patients; however, among patients without
neutropenia, such as surgical ICU patients, this role is less
definitive (32–34). Clinical practices in prophylaxis poli-
cies may vary a great deal between institutions and coun-
tries. While the prophylaxis effectively reduces the inci-
dence of infections caused by fluconazole-sensitive
species, the drug has an impact on the distribution of
causative  Candida species (11,15,32–35). Although
national data on fluconazole usage are available from
Iceland and Norway, they are not comparable (27,28). 
Our study confirms the importance of surgery, cancer,
and hematologic malignancies as factors contributing to
nosocomial candidemia. Only 23% of our candidemia
patients were being treated in ICUs. Approximately twice
the proportion of patients with candidemia who had had
preceding treatment in ICU was reported from Italy
(21,24), but a similar proportion to ours was reported from
France (23). Our patient population included no HIV
patients, which reflects the low prevalence of HIV infec-
tion in Finland (10–16/100,000 population in 1995–1999)
(36). This low prevalence may substantially contribute to
both the lower overall incidence of candidemia and the low
proportion of non-nosocomial Candida infection in
Finland, since in the United States the proportion of can-
didemia cases with HIV infection to all candidemia cases
varied from 10% to 15% (18,25). The contribution of HIV
infection as a predisposing risk factor for candidemia is
further emphasized by a report from Italy, where Candida
spp. was the third most common cause of nosocomial BSI
in HIV patients (37). In France, among cases of nosocomi-
al candidemia, 13% of patients were reported to have HIV
infection during 1990–1995 in one institution (38). 
The high case-fatality ratio we observed in the older
age groups and in patients with a hematologic malignancy
reflects the combination of serious underlying diseases and
the intensity of treatments modifying host defense that
leads to candidemia. In our study, the overall case-fatality
ratio of 15% during 1 week and 35% within 1 month after
the onset of candidemia are similar to ratios reported from
Europe (21,24) and the United States (39), with case-fatal-
ity ratios ranging from 35% to 39%, respectively, within 1
month after onset of candidemia. 
The results of this study demonstrate a low but consis-
tently increasing incidence of candidemia in Finland. The
high case-fatality ratio emphasizes the need for continuous
surveillance to identify changes in predisposing factors for
optimizing prevention policies, including the use of anti-
fungal prophylaxis. 
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